UPDATE: Sarepta Therapeutics (SRPT) Posts Wider-than-Expected Q2 Loss

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($1.35), versus the analyst estimate of ($1.23).

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
• Marathon Petroleum (MPC) PT Raised to $450 at UBS
• Citi upgrades C.H. Robinson to Buy with $185 target, Opens 90-Day upside catalyst watch